New radiation therapy targets hard-to-treat prostate cancer
Disease control
Recruiting now
This study tests a new drug called 177Lu-rhPSMA-10.1 in men with metastatic castrate-resistant prostate cancer, a type of prostate cancer that has spread and no longer responds to hormone therapy. The drug delivers radiation directly to cancer cells. The study has two phases: Pha…
Phase: PHASE1, PHASE2 • Sponsor: Blue Earth Therapeutics Ltd • Aim: Disease control
Last updated May 26, 2026 05:05 UTC